<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JRA</journal-id>
<journal-id journal-id-type="hwp">spjra</journal-id>
<journal-id journal-id-type="nlm-ta">J Renin Angiotensin Aldosterone Syst</journal-id>
<journal-title>Journal of the Renin-Angiotensin-Aldosterone System</journal-title>
<issn pub-type="ppub">1470-3203</issn>
<issn pub-type="epub">1752-8976</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1470320311430990</article-id>
<article-id pub-id-type="publisher-id">10.1177_1470320311430990</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Association of polymorphisms in angiotensin and aldosterone synthase genes of the renin–angiotensin–aldosterone system with high-altitude pulmonary edema</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Srivastava</surname><given-names>Swati</given-names></name>
<xref ref-type="aff" rid="aff1-1470320311430990">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bhagi</surname><given-names>Shuchi</given-names></name>
<xref ref-type="aff" rid="aff1-1470320311430990">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kumari</surname><given-names>Babita</given-names></name>
<xref ref-type="aff" rid="aff1-1470320311430990">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Chandra</surname><given-names>Khem</given-names></name>
<xref ref-type="aff" rid="aff1-1470320311430990">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Sarkar</surname><given-names>Soma</given-names></name>
<xref ref-type="aff" rid="aff2-1470320311430990">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ashraf</surname><given-names>Mohammad Z</given-names></name>
<xref ref-type="aff" rid="aff1-1470320311430990">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1470320311430990"><label>1</label>Genomics Group, Defence Institute of Physiology and Allied Sciences, Delhi, India</aff>
<aff id="aff2-1470320311430990"><label>2</label>Division of Molecular Biology, Defence Institute of Physiology and Allied Sciences, Delhi, India</aff>
<author-notes>
<corresp id="corresp1-1470320311430990">Swati Srivastava, Genomics Group, Defence Institute of Physiology and Allied Sciences, Lucknow Road, Timarpur, Delhi 110054, India. Email: <email>genomics.dipas@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2012</year>
</pub-date>
<volume>13</volume>
<issue>1</issue>
<fpage>155</fpage>
<lpage>160</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2011</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Studies on different populations have suggested variability in individual susceptibility to altitude sickness depending on genetic makeup. The renin–angiotensin–aldosterone system (RAAS) pathway plays a key role in regulation of vascular tone and circulatory homeostasis. The present study was undertaken to investigate the possible association of the RAAS in the development of high-altitude pulmonary edema (HAPE) in lowlanders exposed to high altitude. Three categories of subjects were selected: individuals who developed HAPE on acute induction to high altitude (<italic>HAPE</italic>); individuals tolerant to high-altitude exposure who showed no symptoms of HAPE (resistant controls; <italic>rCON</italic>); and natives of high altitude (<italic>HAN</italic>). Genetic variants in the genes of the RAAS such as renin (<italic>REN</italic>), angiotensin (<italic>AGT</italic>), angiotensin-converting enzyme (<italic>ACE</italic>), aldosterone synthase (<italic>CYP11B2</italic>) and angiotensin II receptor type 1 (<italic>AGTR1</italic>) have been investigated. The T174M polymorphism in <italic>AGT</italic> showed a significant difference in <italic>HAPE</italic> and <italic>HAN</italic> and also <italic>HAN</italic> and <italic>controls</italic>. Also, genotyping in the <italic>CYP11B2</italic> T-344C promoter region resulted in a significant difference between <italic>HAPE</italic> and <italic>HAN</italic> both at genotypic and allelic levels. The genotypic difference was statistically insignificant for the <italic>AGTR1</italic> A1166C 3’ UTR. The present investigation demonstrates a possible association between the polymorphisms existing in the RAAS pathway T174M and <italic>CYP11B2</italic> C-344T and sensitivity of an individual to develop HAPE. The results also indicate the existence of ethnic variation between the <italic>HAN</italic> and the other two groups comprising lowlanders.</p>
</abstract>
<kwd-group>
<kwd>Aldosterone synthase</kwd>
<kwd>angiotensin</kwd>
<kwd>gene polymorphism</kwd>
<kwd>high-altitude pulmonary edema</kwd>
<kwd>renin–angiotensin–aldosterone system</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1470320311430990" sec-type="intro">
<title>Introduction</title>
<p>The high-altitude environment is characterized by low atmospheric pressure, resulting in reduction of partial pressure and hence a lower number of oxygen molecules available per unit volume, a situation referred to as hypobaric hypoxia. The acute syndromes of high altitude are acute mountain sickness (AMS), high-altitude pulmonary edema (HAPE) and high-altitude cerebral edema. HAPE is a non-cardiogenic pulmonary edema whose initial pathogenesis is due to non-uniform pulmonary vasoconstriction leading to pulmonary capillary stress failure and a high permeability type of edema.<sup><xref ref-type="bibr" rid="bibr1-1470320311430990">1</xref></sup> The edema is initially caused due to an increase in pulmonary capillary pressure;<sup><xref ref-type="bibr" rid="bibr2-1470320311430990">2</xref></sup> however, the exact genetic mechanism behind its pathogenesis is unknown. Human adaptations to high-altitude problems involve a number of physiological changes that facilitate the uptake, transport and delivery of oxygen. Since individuals respond differently to these extreme environmental conditions, the variations need to be evaluated on a genetic basis in order to establish any gene–disease association.</p>
<p>The renin–angiotensin–aldosterone system (RAAS) regulates blood pressure and fluid homeostasis in the body. Genetic variants in the genes of the RAAS such as renin (<italic>REN</italic>), angiotensin (<italic>AGT</italic>), angiotensin-converting enzyme (<italic>ACE</italic>), aldosterone synthase (<italic>CYP11B2</italic>) and angiotensin II receptor type 1 (<italic>AGTR1</italic>) have been associated with high risk of susceptibility to HAPE in some populations.<sup><xref ref-type="bibr" rid="bibr3-1470320311430990">3</xref>,<xref ref-type="bibr" rid="bibr4-1470320311430990">4</xref></sup> The RAAS is considered as a circulating endocrine system that releases renin from the juxtaglomerular cells of kidney, which in turn cleaves the precursor angiotensinogen to produce the inactive decapeptide angiotensin. This is further converted to the active octapeptide angiotensin II (AngII) by angiotensin-converting enzyme.<sup><xref ref-type="bibr" rid="bibr5-1470320311430990">5</xref>,<xref ref-type="bibr" rid="bibr6-1470320311430990">6</xref></sup> AngII interacts with distinct AngII receptor subtypes <italic>AGTR1</italic> and <italic>AGTR2</italic>.<sup><xref ref-type="bibr" rid="bibr7-1470320311430990">7</xref></sup> The <italic>AGTR1</italic> receptor belongs to the seven transmembrane class of G-protein-coupled receptors.<sup><xref ref-type="bibr" rid="bibr8-1470320311430990">8</xref></sup> Vasoconstriction, release of aldosterone, stimulation of sympathetic transmission and cellular growth are the known biological actions exclusively mediated by <italic>AGTR1</italic> receptors.<sup><xref ref-type="bibr" rid="bibr9-1470320311430990">9</xref>,<xref ref-type="bibr" rid="bibr10-1470320311430990">10</xref></sup> Association of the angiotensin gene with HAPE has been demonstrated in a Chinese population,<sup><xref ref-type="bibr" rid="bibr3-1470320311430990">3</xref></sup> and angiotensin II receptor type 1 (<italic>AGTR1</italic>) with HAPE in a Japanese population.<sup><xref ref-type="bibr" rid="bibr4-1470320311430990">4</xref></sup></p>
<p>Aldosterone synthase (<italic>CYP11B2</italic>) is a mineralocorticoid playing a key role in the regulation of sodium–water homeostasis by causing reabsorption of salt from renal tubules.<sup><xref ref-type="bibr" rid="bibr11-1470320311430990">11</xref></sup> As a result, blood pressure rises in the body, leading to higher risk for development of HAPE. Lower levels of aldosterone synthase, and consequently aldosterone, point towards a selective advantage at high altitude.<sup><xref ref-type="bibr" rid="bibr12-1470320311430990">12</xref></sup> Also, high-altitude-induced dieresis is associated with marked changes in sodium and water-regulating hormones which are regulated by the RAAS,<sup><xref ref-type="bibr" rid="bibr13-1470320311430990">13</xref></sup> thereby playing an important role in regulating vascular tone in HAPE.<sup><xref ref-type="bibr" rid="bibr14-1470320311430990">14</xref></sup></p>
<p>We hypothesized that inter-individual differences in the genes of the RAAS pathway could be the genetic basis of susceptibility to HAPE. The present study examines the role of polymorphisms in angiotensin, angiotensin II receptor type 1 and aldosterone synthase genes for sensitivity of an individual to develop HAPE.</p>
</sec>
<sec id="section2-1470320311430990" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="section3-1470320311430990">
<title>Subjects</title>
<p>The study was approved by the institutional ethical committee, and written informed consent was obtained before recruitment of volunteers for this study. The subjects were age and gender matched (all males). The study population consisted of three groups of unrelated human volunteers exposed to high-altitude conditions of Leh, Ladakh (in the Himalayan region of India), situated at an altitude of 3524 m (11,562 ft): resistant controls (<italic>rCON</italic>), consisting of subjects who did not suffer from any HAPE or related illness after exposure to high altitude, individuals suffering from high-altitude pulmonary edema (<italic>HAPE</italic>), and natives of high altitude (<italic>HAN</italic>). The subjects who participated in the study were all Indian Army personnel; natives of Leh, Ladakh, comprised the <italic>HAN</italic> group, and subjects in the <italic>rCON</italic> and <italic>HAPE</italic> groups were rapidly inducted to high altitude. After a period of 72 h of exposure to high-altitude conditions, <italic>HAPE</italic> patient blood samples were collected from 153 General Hospital, Leh, with the support of the High Altitude Medical Research Centre, Leh, and physiological parameters were measured after admission to hospital and confirmatory diagnostic investigations (chest X-ray) for HAPE. For the <italic>rCON</italic> group, subjects were selected on the basis of similar duration and altitude of stay, and physiological variables such as age, body weight, blood pressure and saturation of peripheral oxygen (SpO<sub>2</sub>) were measured. The measurements and blood sample collection in <italic>rCON</italic> and <italic>HAN</italic> groups were performed in the morning before breakfast. Blood pressure (BP) was measured using a mercury sphygmomanometer, while SpO<sub>2</sub> was measured using a Pulse Oximeter (N-20, Nellcor, USA). A volume of 5 ml of venous blood was collected in K3 EDTA tubes (EDTA avoids the coagulation cascade and blood can be stored in its original form) and stored at -20°C until processing.</p>
</sec>
<sec id="section4-1470320311430990">
<title>Isolation of DNA</title>
<p>Stored EDTA tubes containing blood were taken and thawed on ice. Genomic DNA was extracted from peripheral blood leukocytes according to the standard phenol chloroform extraction method. Briefly, DNA was isolated by phenol extraction from sodium dodecyl sulphate-lysed, proteinase K-treated cells by overnight incubation at 37°C. Genomic DNA was checked quantitatively using the DNA/RNA Quant calculator (Amersham Pharmacia, UK). For qualitative analysis, samples (100 ng/µl) were loaded on a 0.7% agarose gel containing ethidium bromide, run for approximately 20 min and visualized under UV.</p>
</sec>
<sec id="section5-1470320311430990">
<title>Genotypic analysis</title>
<p>Five single nucleotide polymorphisms (SNPs) from three genes, namely angiotensin (<italic>AGT</italic>), angiotensin II receptor type 1 (<italic>AGTR1</italic>) and the aldosterone synthase (<italic>CYP11B2</italic>) gene from the RAAS pathway, were genotyped using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) and tested for association with HAPE.</p>
<p>These polymorphisms were selected based on their functional relevance in the published literature. Specific regions of genes such as <italic>AGT</italic> T174M (rs4762), where a missense mutation from nucleotide C to T at position 1128 changes amino acid threonine to methionine and Glu53stop, a non-sense mutation in <italic>AGT</italic> gene, both at exon2, <italic>AGTR1</italic> A1166C (rs5186) at 3’ untranslated region (UTR), <italic>AGTR1</italic> A-777T (rs275651) and <italic>CYP11B2</italic> C-344T (rs1799998) both at promoter region, were amplified using 1× buffer containing 0.5 mM MgCl<sub>2</sub>, 2.2 mM deoxynucleoside triphosphate (Amersham Pharmacia, UK), 0.6 U Taq DNA polymerase (Bangalore Genei, India) and specific primer sequences along with 100–150 ng of DNA in a final volume of 25 µl and determined by PCR-RFLP. Primer sequences and amplification details for these polymorphic regions<sup><xref ref-type="bibr" rid="bibr15-1470320311430990">15</xref>,<xref ref-type="bibr" rid="bibr16-1470320311430990">16</xref></sup> are listed in <xref ref-type="table" rid="table1-1470320311430990">Table 1</xref>. Amplified gene sequences were digested by specific restriction enzymes (New England Biolabs, UK), and the digested PCR products were resolved on 2–3% agarose gels (<xref ref-type="table" rid="table1-1470320311430990">Table 1</xref>) stained with ethidium bromide. The restriction enzymes used for digestion were as follows: <italic>Dde</italic>I for <italic>AGTR1</italic> A1166C, <italic>Alu</italic>I for <italic>AGTR1</italic> A-777T, <italic>Nco</italic>I for <italic>AGT</italic> T174M, <italic>Pvu</italic>II for AGT Glu53stop and <italic>Hae</italic>III for <italic>CYP11B2</italic> C-344T. Gel images were visualized under UV in a Fluor-S Multi-Imager (BioRad, USA). The quality control of the genotyping experiments was exercised by randomly profiling (PCR amplification followed by restriction digestion and electrophoresis) around 25–30% of the samples after the initial profiling of the samples was carried out.</p>
<table-wrap id="table1-1470320311430990" position="float">
<label>Table 1.</label>
<caption>
<p>Details of single nucleotide polymorphisms studied in the renin–angiotensin–aldosterone system pathway showing the primer sequences, PCR product size, annealing temperature, restriction enzyme, digestion temperature and the fragment sizes.</p>
</caption>
<graphic alternate-form-of="table1-1470320311430990" xlink:href="10.1177_1470320311430990-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Gene olymorphism</th>
<th align="left">Primer sequence</th>
<th align="left">PCR roduct size (bp)</th>
<th align="left">Annealing temperature</th>
<th align="left">Restriction enzyme</th>
<th align="left">Digestion temperature and time</th>
<th align="left">Fragment size (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGTR1 A1166C 3’UTR</td>
<td>F; ATAATGTAAGCTCATCCACC<break/>R; GAGATTGCATTTCTGGTCAGT</td>
<td>359</td>
<td>55°C</td>
<td><italic>Dde</italic>I</td>
<td>37°C, 4hrs</td>
<td>A = 359<break/>C = 220, 139</td>
</tr>
<tr>
<td>AGTR1 A-777 promoter</td>
<td>F; AGTCACCCTACTCACCTAGCTAACA<break/>R; AGACATCACGAGACTACAGAGCAA</td>
<td>192</td>
<td>60°C</td>
<td><italic>Alu</italic>I</td>
<td>37°C, 3 hrs</td>
<td>A = 173, 19<break/>C = 192</td>
</tr>
<tr>
<td>AGT T174M exon2</td>
<td>F; CAATTCAGGCCAAGACATCC<break/>R; GCCAGAGCCAGCAGAGAG</td>
<td>674</td>
<td>58°C</td>
<td><italic>Nco</italic>I</td>
<td>37°C, 3hrs</td>
<td>C = 502, 172<break/>T = 256, 246, 172</td>
</tr>
<tr>
<td>AGT Glu53stop exon2</td>
<td>F; ACCATCCTCTGCCTCCTG<break/>R; TCCAAGGCTCCCAGATAGAG</td>
<td>398</td>
<td>58°C</td>
<td><italic>Pvu</italic>II</td>
<td>37°C, O/N</td>
<td>C = 102, 102, 194<break/>T = 204, 194</td>
</tr>
<tr>
<td>CYP11B2 C- 344T promoter</td>
<td>F; TGGAGGGTGTACCTGTGTGTCA<break/>R; GTCCTGCTGGTCTGAGGATG</td>
<td>270</td>
<td>57°C</td>
<td><italic>Hae</italic>III</td>
<td>37°C, O/N</td>
<td>T = 189, 81<break/>C = 118, 71, 81</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section6-1470320311430990">
<title>Statistical analysis</title>
<p>Genotypic and allelic frequencies were calculated. The χ<sup>2</sup> test and Fisher’s exact test were carried out using Medcalc software (<ext-link ext-link-type="uri" xlink:href="http://www.medcalc.org/">http://www.medcalc.org/</ext-link>). These frequencies were also tested for Hardy–Weinberg Equilibrium (<ext-link ext-link-type="uri" xlink:href="http://www.tufts.edu/~mcourt01/Court%20lab%20-%20%20HW%20%20%20calculator.xls">www.tufts.edu/~mcourt01/Court%20lab%20-%20 HW %20 calculator.xls</ext-link>). For all tests a <italic>p</italic>-value of ≤ 0.05 was considered significant. Genotypic distribution between the two significantly associated gene polymorphisms <italic>AGT</italic> T174M and <italic>CYP11B2</italic> C-344T was calculated.</p>
</sec></sec>
<sec id="section7-1470320311430990" sec-type="results">
<title>Results</title>
<sec id="section8-1470320311430990">
<title>Baseline variables</title>
<p>In order to understand the role of physiological factors in development of HAPE, physiological baseline variables (listed in <xref ref-type="table" rid="table2-1470320311430990">Table 2</xref>) were recorded before the collection of blood samples. Age and body weight-matched subjects demonstrated a similar systolic and diastolic BP, whereas a noticeable increase in heart rate and decrease in SpO2 was observed in <italic>HAPE</italic> as compared with both <italic>rCON</italic> and <italic>HAN</italic>.</p>
<table-wrap id="table2-1470320311430990" position="float">
<label>Table 2.</label>
<caption>
<p>Physiological data shown as mean ± Standard deviation.</p>
</caption>
<graphic alternate-form-of="table2-1470320311430990" xlink:href="10.1177_1470320311430990-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">HAPE (80)</th>
<th align="left">r-CONTROLS (48)</th>
<th align="left">HAN (67)</th>
</tr>
</thead>
<tbody>
<tr>
<td><bold>Age (years)</bold></td>
<td>29.62 ± 7.5</td>
<td>28.29 ± 6.9</td>
<td>29.10 ± 6.49</td>
</tr>
<tr>
<td><bold>Body Weight (kg)</bold></td>
<td>66.13 ± 8.0</td>
<td>68.64 ± 18.8</td>
<td>60.58 ± 5.8</td>
</tr>
<tr>
<td><bold>Heart rate (rate/min)</bold></td>
<td>109.61 ± 16.5</td>
<td>80.92 ± 13.3</td>
<td>73.5 ± 7.5</td>
</tr>
<tr>
<td><bold>SBP (mmHg)</bold></td>
<td>123.83 ± 10.7</td>
<td>112.81 ± 9.6</td>
<td>115.63 ± 8.8</td>
</tr>
<tr>
<td><bold>DBP (mmHg)</bold></td>
<td>80.51 ± 8.3</td>
<td>81.14 ± 10.7</td>
<td>76.55 ± 6.6</td>
</tr>
<tr>
<td><bold>SaO2 (%)</bold></td>
<td>70.69 ± 11.15</td>
<td>91.5 ± 2.1</td>
<td>91.34 ± 2.7</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1470320311430990">
<p>SBP, systolic blood pressure; DBP, diastolic blood pressure; SaO<sub>2</sub>: arterial oxygen saturation</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section9-1470320311430990">
<title>Monomorphic polymorphisms</title>
<p>Glu53stop, a non-sense mutation in <italic>AGT</italic> gene and the A-777T single nucleotide polymorphism in the <italic>AGTR1</italic> gene were found to be monomorphic in all the three groups and hence were not considered for further analysis. These findings are in concurrence with the normative data of a north Indian and south Indian population study.<sup><xref ref-type="bibr" rid="bibr15-1470320311430990">15</xref></sup></p>
</sec>
<sec id="section10-1470320311430990">
<title>Angiotensin gene</title>
<p>Genotyping of the T174M polymorphism located in exon 2 region of the <italic>AGT</italic> gene was performed in 71 HAPE patients (<italic>HAPE</italic>), 29 resistant controls (<italic>rCON</italic>) and 39 high-altitude natives (<italic>HAN</italic>). Genotyping of this polymorphism revealed significant χ<sup>2</sup> difference between <italic>HAPE</italic> and <italic>HAN</italic> (<italic>p</italic> = 0.024, <xref ref-type="table" rid="table3-1470320311430990">Table 3</xref>) and also between <italic>HAN</italic> and <italic>rCON</italic> (<italic>p</italic> = 0.03, <xref ref-type="table" rid="table3-1470320311430990">Table 3</xref>). As a result of the Fisher exact test, a significant difference in the allelic frequencies was also observed in the angiotensin gene polymorphism between <italic>HAPE</italic> and <italic>HAN</italic> (<italic>p</italic> = 0.01, <xref ref-type="table" rid="table3-1470320311430990">Table 3</xref>) and <italic>HAN</italic> and <italic>rCON</italic> (<italic>p</italic> = 0.03, <xref ref-type="table" rid="table3-1470320311430990">Table 3</xref>). The frequency of distribution of the CC, CT and TT genotypes was 38 (53.52%), 32 (45.07%) and 1 (1.40%) in <italic>HAPE</italic>, 15 (51.72%), 14 (48.27%) and 0 in <italic>rCON</italic> and 31 (79.48%), 8 (20.51%) and 0 in <italic>HAN</italic>. The distribution of <italic>AGT</italic> genotype in the native (<italic>HAN</italic>) and resistant control (<italic>rCON</italic>) groups was in Hardy–Weinberg equilibrium. However, the <italic>HAPE</italic> population deviated from Hardy–Weinberg Equilibrium with a <italic>p</italic>-value of 0.04.</p>
<table-wrap id="table3-1470320311430990" position="float">
<label>Table 3.</label>
<caption>
<p>Observed genotypic and allelic frequencies of polymorphisms in <italic>AGT, CYP11B2T</italic> and <italic>AGTR1</italic> genes. The table also shows the χ<sup>2</sup> test and Fisher’s exact test values</p>
</caption>
<graphic alternate-form-of="table3-1470320311430990" xlink:href="10.1177_1470320311430990-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">AGT Thr 174 Met</th>
<th align="left" colspan="3">Genotypes (frequency)</th>
<th align="left" colspan="2">Allele frequency</th>
<th/>
<th/>
<th/>
<th/>
</tr>
<tr>
<th align="left">Group</th>
<th align="left">CC</th>
<th align="left">CT</th>
<th align="left">TT</th>
<th align="left">C</th>
<th align="left">T</th>
<th/>
<th align="left">χ<sup>2</sup></th>
<th align="left"><italic>p</italic>-value</th>
<th align="left">Fisher’s exact (<italic>p</italic>-value)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HAPE (<italic>n</italic> = 71)</td>
<td>38 (53.52)</td>
<td>32 (45.07)</td>
<td>1 (1.40)</td>
<td>76.05</td>
<td>23.94</td>
<td><bold>HAPE/HAN</bold></td>
<td>7.43</td>
<td><bold>0.024</bold></td>
<td><bold>0.018</bold></td>
</tr>
<tr>
<td>CONTROL (<italic>n</italic> = 29)</td>
<td>15 (51.72)</td>
<td>14 (48.27)</td>
<td>0</td>
<td>75.86</td>
<td>24.14</td>
<td><bold>HAPE/Control</bold></td>
<td>0.46</td>
<td>0.79</td>
<td>1</td>
</tr>
<tr>
<td>HAN (<italic>n</italic> = 39)</td>
<td>31 (79.48)</td>
<td>8 (20.51)</td>
<td>0</td>
<td>89.74</td>
<td>10.26</td>
<td><bold>HAN/Control</bold></td>
<td>4.65</td>
<td><bold>0.03</bold></td>
<td><bold>0.035</bold></td>
</tr>
<tr>
<td><bold>CYP11B2 C-344T</bold></td>
<td colspan="3"><bold>Genotypes (frequency)</bold></td>
<td colspan="2"><bold>Allele frequency</bold></td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td><bold>Group</bold></td>
<td><bold>TT</bold></td>
<td><bold>TC</bold></td>
<td><bold>CC</bold></td>
<td><bold>T</bold></td>
<td><bold>C</bold></td>
<td/>
<td><bold>χ<sup>2</sup></bold></td>
<td><bold><italic>p</italic>-value</bold></td>
<td><bold>Fisher’s exact (<italic>p</italic>-value)</bold></td>
</tr>
<tr>
<td>HAPE (<italic>n</italic> = 80)</td>
<td>30 (37.5)</td>
<td>42 (52.5)</td>
<td>8 (10)</td>
<td>63.75</td>
<td>36.25</td>
<td><bold>HAPE/HAN</bold></td>
<td>7.44</td>
<td><bold>0.02</bold></td>
<td><bold>0.01</bold></td>
</tr>
<tr>
<td>CONTROL (<italic>n</italic> = 48)</td>
<td>22 (45.83)</td>
<td>22 (45.83)</td>
<td>4 (8.33)</td>
<td>68.75</td>
<td>31.25</td>
<td><bold>HAPE/Control</bold></td>
<td>0.68</td>
<td>0.64</td>
<td>0.49</td>
</tr>
<tr>
<td>HAN (<italic>n</italic> = 67)</td>
<td>39 (58.20)</td>
<td>26 (38.8)</td>
<td>2 (2.98)</td>
<td>77.61</td>
<td>22.39</td>
<td><bold>HAN/Control</bold></td>
<td>2.67</td>
<td>0.26</td>
<td>0.17</td>
</tr>
<tr>
<td><bold>AGTR1 A1166C</bold></td>
<td colspan="3"><bold>Genotypes (frequency)</bold></td>
<td colspan="2"><bold>Allele frequency</bold></td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td><bold>Group</bold></td>
<td><bold>AA</bold></td>
<td><bold>AC</bold></td>
<td><bold>CC</bold></td>
<td><bold>A</bold></td>
<td><bold>C</bold></td>
<td/>
<td><bold>χ<sup>2</sup></bold></td>
<td><bold><italic>p</italic>-value</bold></td>
<td><bold>Fisher’s exact (<italic>p</italic>-value)</bold></td>
</tr>
<tr>
<td>HAPE (<italic>n</italic> = 80)</td>
<td>44 (55)</td>
<td>36 (45)</td>
<td>0</td>
<td>77.5</td>
<td>22.5</td>
<td><bold>HAPE/HAN</bold></td>
<td>0.01</td>
<td>0.89</td>
<td>0.88</td>
</tr>
<tr>
<td>CONTROL (<italic>n</italic> = 48)</td>
<td>22 (45.83)</td>
<td>26 (54.16)</td>
<td>0</td>
<td>72.91</td>
<td>27.08</td>
<td><bold>HAPE/Control</bold></td>
<td>0.67</td>
<td>0.41</td>
<td>0.45</td>
</tr>
<tr>
<td>HAN (<italic>n</italic> = 59)</td>
<td>34 (57.62)</td>
<td>25 (42.37)</td>
<td>0</td>
<td>78.81</td>
<td>21.19</td>
<td><bold>HAN/Control</bold></td>
<td>1.04</td>
<td>0.3</td>
<td>0.33</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section11-1470320311430990">
<title>Aldosterone synthase gene</title>
<p>The χ<sup>2</sup> value showed a significant difference between 80 patients of <italic>HAPE</italic> and 67 <italic>HAN</italic>, as obtained from genotyping of the <italic>CYP11B2</italic> C-344T promoter (<italic>p</italic> = 0.02, <xref ref-type="table" rid="table3-1470320311430990">Table 3</xref>). Allelic frequency also showed a significant difference between <italic>HAPE</italic> and <italic>HAN</italic> (<italic>p</italic> = 0.01). The frequency distribution of the three genotypes TT, TC and CC was 30 (37.5%), 42 (52.5%) and 8 (10%), respectively, for <italic>HAPE</italic>; 22 (45.83%), 22 (45.83%) and 4 (8.33%) for <italic>rCON</italic>; and 39 (58.20%), 26 (38.8%) and 2 (2.98%) for <italic>HAN</italic>. No significant difference was observed between <italic>rCON</italic> versus <italic>HAPE</italic> and <italic>rCON</italic> versus <italic>HAN</italic>. All the groups studied followed Hardy–Weinberg Equilibrium.</p>
</sec>
<sec id="section12-1470320311430990">
<title>Angiotensin II type I receptor gene</title>
<p>The A1166C polymorphism of the <italic>AGTR1</italic> receptor gene showed no statistically significant difference in allelic and genotypic frequency distribution between <italic>HAPE, rCON</italic> and <italic>HAN</italic>, indicating that this SNP is not associated with HAPE. In all the subjects under study, none demonstrated the CC genotype. The frequency distribution of AA and AC genotypes of this polymorphism was 44 (55%) and 36 (45%), respectively, for <italic>HAPE</italic>; 22 (45.83%) and 26 (54.15%) for <italic>rCON</italic>; and 34 (57.62%) and 25 (42.37%) for <italic>HAN</italic>. Significant deviation from Hardy–Weinberg Equilibrium was observed in all the three groups under study with a <italic>p</italic>-value &lt;0.05. This deviation is probably because of absence of the homozygous CC genotype in our study population.</p>
</sec>
<sec id="section13-1470320311430990">
<title>Gene–gene interaction analysis</title>
<p>A combined genotypic interaction analysis was carried out between the two significantly associated gene polymorphisms, i.e. <italic>AGT</italic> T174M and <italic>CYP11B2</italic> C-344T. The genotypic interaction study showed a clear distinction between the allelic combination of <italic>HAPE, rCON</italic> and <italic>HAN</italic>; however, no definite pattern could be predicted. The <italic>HAN</italic> population represented a higher percentage genotypic combination of homozygous <italic>AGT</italic> CC and <italic>CYP11B2</italic> TT genotypes (46.15%), compared with <italic>HAPE</italic> (22.72%) and <italic>rCON</italic> (17.82%).</p>
</sec></sec>
<sec id="section14-1470320311430990" sec-type="discussion">
<title>Discussion</title>
<p>In the present investigation, allele frequencies for the five different polymorphisms in three gene components of candidate genes of the renin–angiotensin pathway were studied in individuals suffering from HAPE compared with resistant controls and high-altitude natives. No significant difference was observed between the subjects of the HAPE group and resistant controls in any of the genotyping results, which indicates that both groups have a similar frequency of genotypes. This may be due to the fact that both these groups comprise lowlanders, as opposed to high-altitude natives. The prominent finding of the present investigation includes a significant difference observed between <italic>AGT</italic> T174M and <italic>CYP11B2</italic> C-344T in HAPE patients compared with high-altitude natives. Although the genetic mechanism of susceptibility and resistance to HAPE is poorly understood, the current findings indicate the involvement of these SNPs of the RAAS pathway in genetic adaptation to this disease.</p>
<p><italic>AGT</italic> is an important candidate gene of the RAAS pathway which has been shown to play a crucial role in cardiovascular diseases. In 1992, Jeunemaitre et al.<sup><xref ref-type="bibr" rid="bibr17-1470320311430990">17</xref></sup> reported the role of the SNP M235T in the development of hypertension, wherein the TT homozygous genotype was also suggested to be involved. Also, recently Stobdan et al.<sup><xref ref-type="bibr" rid="bibr18-1470320311430990">18</xref></sup> showed a significant association of the MM homozygous genotype of this polymorphism with HAPE. In the present study, we have investigated another commonly occurring polymorphism in the <italic>AGT</italic> gene, i.e. T174M present in exon 2, and found a significant genotypic difference between <italic>HAPE</italic> and <italic>HAN</italic> and also between <italic>rCON</italic> and <italic>HAN</italic> groups. Also, the allelic difference between <italic>HAPE</italic> versus <italic>HAN</italic> and <italic>rCON</italic> versus <italic>HAN</italic> was statistically significant (see <xref ref-type="table" rid="table3-1470320311430990">Table 3</xref>). This difference could be due to ethnic variation between high-altitude natives and the other two groups, HAPE and resistant controls. However, there is scope for further exploration of this SNP in a larger population to obtain some conclusive evidence of its relationship with HAPE.</p>
<p>The aldosterone synthase gene (<italic>CYP11B2</italic>) has also been reported to be significantly associated with hypertension. Association of the -344T allele of this gene with increased risk of hypertension in African Americans has been reported.<sup><xref ref-type="bibr" rid="bibr19-1470320311430990">19</xref></sup> Also, association of the -344TT genotype with higher genetic susceptibility to HAPE, along with two other polymorphisms of ACE gene, has been demonstrated in a genotypic interaction study.<sup><xref ref-type="bibr" rid="bibr3-1470320311430990">3</xref></sup> Our results also show significant χ<sup>2</sup>difference between <italic>HAPE</italic> and <italic>HAN</italic> both for genotypic and allelic frequencies. This difference could partially be attributed to the ethnic variation between the <italic>HAN</italic> (high-altitude population) and <italic>HAPE</italic> (sea-level population) groups. However, the fact that no significant difference has been found between <italic>rCON</italic> (which again is a sea-level population) and <italic>HAN</italic> groups, hence the possibility of this SNP being linked to the susceptibility to HAPE, cannot be ignored. The percentage of homozygous -344TT was found to be 37.5% in <italic>HAPE</italic> and 58.2% in <italic>HAN</italic>. Also, the allelic percentage of -344T allele was lower in <italic>HAPE</italic> (63.75%) compared with <italic>HAN</italic> (77.61%). This is in concurrence with the study by Rajput et al.,<sup><xref ref-type="bibr" rid="bibr12-1470320311430990">12</xref></sup> where the wild-type allele -344T was over-represented in Himalayan natives, and where they suggested its association with high-altitude adaptation.</p>
<p>Association of the <italic>AGTR1</italic> A1166C polymorphism with pulmonary arterial hypertension has been shown recently.<sup><xref ref-type="bibr" rid="bibr20-1470320311430990">20</xref></sup> The pathogenesis of pulmonary hypertension is also critical for the development of HAPE. However, variants of the angiotensin receptor (<italic>AGTR1</italic> and <italic>AGTR2</italic>) have failed to associate with AMS and HAPE in various ethnic groups in earlier studies.<sup><xref ref-type="bibr" rid="bibr21-1470320311430990">21</xref>,<xref ref-type="bibr" rid="bibr22-1470320311430990">22</xref></sup> In the present study, our small population size shows no significant difference between individuals suffering from <italic>HAPE</italic> and the other two groups, resistant control and <italic>HAN</italic>. This could be due to different adaptive responses to possible geographical separation and exposure to altitude of these populations.</p>
</sec>
<sec id="section15-1470320311430990" sec-type="conclusions">
<title>Conclusion</title>
<p>In summary, the genetic makeup of lowlanders (i.e. patients with HAPE and tolerant controls) differs from that of high-altitude natives. The data generated from the present study show a significant role of the RAAS pathway, especially <italic>CYP11B2</italic>, in high-altitude acclimatization and could be evaluated further for finding genetic markers for the development of HAPE. It can be inferred that the pathogenesis of HAPE can be attributed to the polymorphisms occurring in the RAAS to some extent. However, a complete validation of these polymorphisms in a different population and with a larger number of samples is required for any conclusive evidence.</p>
</sec>
</body>
<back>
<ack><p>The authors would like to thank the Officer in Charge and other supporting staff of HAMRC &amp; 153 GH, Leh, for their cooperation and logistic support in collection of blood samples.</p></ack>
<fn-group>
<fn fn-type="financial-disclosure">
<p>This project was funded by Defense Research &amp; Development Organization, India.</p>
</fn>
<fn fn-type="conflict">
<p>The authors declare that they have no conflict of interest.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1470320311430990">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bartsch</surname><given-names>P</given-names></name>
<name><surname>Mairbaurl</surname><given-names>H</given-names></name>
<name><surname>Maggiorini</surname><given-names>M</given-names></name>
<name><surname>Swenson</surname><given-names>ER</given-names></name>
</person-group>. <article-title>Physiological aspects of high altitude pulmonary edema</article-title>. <source>J Appl Physiol</source> <year>2005</year>; <volume>98</volume>: <fpage>1101</fpage>–<lpage>1110</lpage>.</citation>
</ref>
<ref id="bibr2-1470320311430990">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Maggiorini</surname><given-names>M</given-names></name>
<name><surname>Melot</surname><given-names>C</given-names></name>
<name><surname>Pierre</surname><given-names>S</given-names></name>
<name><surname>Pfeiffer</surname><given-names>F</given-names></name>
<name><surname>Greve</surname><given-names>I</given-names></name>
<name><surname>Sartori</surname><given-names>C</given-names></name><etal/>
</person-group>. <article-title>High altitude pulmonary edema is initially caused by an increase in capillary pressure</article-title>. <source>Circulation</source> <year>2001</year>; <volume>103</volume>: <fpage>2078</fpage>–<lpage>2083</lpage>.</citation>
</ref>
<ref id="bibr3-1470320311430990">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Qi</surname><given-names>Y</given-names></name>
<name><surname>Niu</surname><given-names>W</given-names></name>
<name><surname>Zhu</surname><given-names>T</given-names></name>
<name><surname>Zhou</surname><given-names>W</given-names></name>
<name><surname>Qiu</surname><given-names>C</given-names></name>
</person-group>. <article-title>Synergetic effect of the genetic polymorphisms of the renin-angiotensin-aldosterone system on high altitude pulmonary edema: a study from Qinghai-Tibet altitude</article-title>. <source>Eur J Epidemiol</source> <year>2008</year>; <volume>23</volume>: <fpage>143</fpage>–<lpage>152</lpage>.</citation>
</ref>
<ref id="bibr4-1470320311430990">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hotta</surname><given-names>J</given-names></name>
<name><surname>Hanaoka</surname><given-names>M</given-names></name>
<name><surname>Droma</surname><given-names>Y</given-names></name>
<name><surname>Katsuyama</surname><given-names>Y</given-names></name>
<name><surname>Ota</surname><given-names>M</given-names></name>
<name><surname>Kobayashi</surname><given-names>T</given-names></name>
</person-group>. <article-title>Polymorphisms of renin–angiotensin system genes with high altitude pulmonary edema in Japanese subjects</article-title>. <source>Chest</source> <year>2004</year>; <volume>126</volume>: <fpage>825</fpage>–<lpage>830</lpage>.</citation>
</ref>
<ref id="bibr5-1470320311430990">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Campbell</surname><given-names>DJ</given-names></name>
</person-group>. <article-title>Circulating and tissue angiotensin systems</article-title>. <source>J Clin Invest</source> <year>1987</year>; <volume>79</volume>: <fpage>1</fpage>–<lpage>6</lpage>.</citation>
</ref>
<ref id="bibr6-1470320311430990">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Johnston</surname><given-names>CI</given-names></name>
</person-group>. <article-title>Franz Volhard Lecture. Renin–angiotensin system: a dual tissue and hormonal system for cardiovascular control</article-title>. <source>J Hypertens</source> <year>1992</year>; <volume>10</volume>: <fpage>13</fpage>–<lpage>26</lpage>.</citation>
</ref>
<ref id="bibr7-1470320311430990">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>de Gasparo</surname><given-names>M</given-names></name>
<name><surname>Husain</surname><given-names>A</given-names></name>
<name><surname>Alexander</surname><given-names>W</given-names></name>
<name><surname>Catt</surname><given-names>KJ</given-names></name>
<name><surname>Chiu</surname><given-names>AT</given-names></name>
<name><surname>Drew</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Proposed update of angiotensin receptor nomenclature</article-title>. <source>Hypertension</source> <year>1995</year>; <volume>25</volume>: <fpage>924</fpage>–<lpage>927</lpage>.</citation>
</ref>
<ref id="bibr8-1470320311430990">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Griendling</surname><given-names>KK</given-names></name>
<name><surname>Alexander</surname><given-names>RW</given-names></name>
</person-group>. <article-title>The angiotensin (AGTR1) receptor</article-title>. <source>Semin Nephrom</source> <year>1993</year>; <volume>13</volume>: <fpage>558</fpage>–<lpage>566</lpage>.</citation>
</ref>
<ref id="bibr9-1470320311430990">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Timmermans</surname><given-names>PB</given-names></name>
<name><surname>Benfield</surname><given-names>P</given-names></name>
<name><surname>Chiu</surname><given-names>AT</given-names></name>
<name><surname>Herblin</surname><given-names>WF</given-names></name>
<name><surname>Wong</surname><given-names>PC</given-names></name>
<name><surname>Smith</surname><given-names>RD</given-names></name>
</person-group>. <article-title>Angiotensin II receptor and functional correlates</article-title>. <source>Am J Hyperten</source> <year>2004</year>; <volume>5</volume>: <fpage>221</fpage>–<lpage>235</lpage>.</citation>
</ref>
<ref id="bibr10-1470320311430990">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Timmermans</surname><given-names>PB</given-names></name>
<name><surname>Wong</surname><given-names>PC</given-names></name>
<name><surname>Chiu</surname><given-names>AT</given-names></name>
<name><surname>Herblin</surname><given-names>WF</given-names></name>
<name><surname>Benfield</surname><given-names>P</given-names></name>
<name><surname>Carini</surname><given-names>DJ</given-names></name><etal/>
</person-group>. <article-title>Angiotensin II receptors and angiotensin II receptor antagonists</article-title>. <source>Pharmacol Rev</source> <year>1993</year>; <volume>45</volume>: <fpage>205</fpage>–<lpage>251</lpage>.</citation>
</ref>
<ref id="bibr11-1470320311430990">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stobdan</surname><given-names>T</given-names></name>
<name><surname>Karar</surname><given-names>J</given-names></name>
<name><surname>Pasha</surname><given-names>MAQ</given-names></name>
</person-group>. <article-title>High altitude adaptation: Genetic Perspective</article-title>. <source>High Alt Med Biol</source> <year>2008</year>; <volume>9</volume>: <fpage>140</fpage>–<lpage>147</lpage>.</citation>
</ref>
<ref id="bibr12-1470320311430990">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rajput</surname><given-names>C</given-names></name>
<name><surname>Arif</surname><given-names>E</given-names></name>
<name><surname>Vibhuti</surname><given-names>A</given-names></name>
<name><surname>Stobdan</surname><given-names>T</given-names></name>
<name><surname>Khan</surname><given-names>AP</given-names></name>
<name><surname>Norboo</surname><given-names>T</given-names></name><etal/>
</person-group>. <article-title>Predominance of interaction among wild-type alleles of CYP11B2 in Himalayan natives associates with high altitude adaptation</article-title>. <source>Biochem Biophys Res Commun</source> <year>2006</year>; <volume>348</volume>: <fpage>735</fpage>–<lpage>740</lpage>.</citation>
</ref>
<ref id="bibr13-1470320311430990">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zaccaria</surname><given-names>M</given-names></name>
<name><surname>Rocco</surname><given-names>S</given-names></name>
<name><surname>Noventa</surname><given-names>D</given-names></name>
<name><surname>Varnier</surname><given-names>M</given-names></name>
<name><surname>Opocher</surname><given-names>G</given-names></name>
</person-group>. <article-title>Sodium regulating hormones at high altitude: basal and post-exercise levels</article-title>. <source>J Clin Endocrinol Metab</source> <year>1998</year>; <volume>83</volume>: <fpage>570</fpage>–<lpage>574</lpage>.</citation>
</ref>
<ref id="bibr14-1470320311430990">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marshall</surname><given-names>RP</given-names></name>
</person-group>. <article-title>The pulmonary renin-angiotensin system</article-title>. <source>Curr Pharm Des</source> <year>2003</year>; <volume>9</volume>: <fpage>715</fpage>–<lpage>722</lpage>.</citation>
</ref>
<ref id="bibr15-1470320311430990">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Prasad</surname><given-names>P</given-names></name>
<name><surname>Thelma</surname><given-names>BK</given-names></name>
</person-group>. <article-title>Normative genetic profiles of RAAS pathway gene polymorphisms in north Indian and south Indian populations</article-title>. <source>Hum Biol</source> <year>2007</year>; <volume>79</volume>: <fpage>241</fpage>–<lpage>254</lpage>.</citation>
</ref>
<ref id="bibr16-1470320311430990">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rupert</surname><given-names>JL</given-names></name>
<name><surname>Kidd</surname><given-names>KK</given-names></name>
<name><surname>Norman</surname><given-names>LE</given-names></name>
<name><surname>Monsalve</surname><given-names>MV</given-names></name>
<name><surname>Hochachka</surname><given-names>PW</given-names></name>
<name><surname>Devine</surname><given-names>DV</given-names></name>
</person-group>. <article-title>Genetic polymorphisms in the renin-angiotensin system in high altitude and low altitude native American populations</article-title>. <source>Ann Hum Genet</source> <year>2003</year>; <volume>67</volume>: <fpage>17</fpage>–<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr17-1470320311430990">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jeunemaitre</surname><given-names>X</given-names></name>
<name><surname>Soubrier</surname><given-names>F</given-names></name>
<name><surname>Kotelevtsev</surname><given-names>YV</given-names></name>
<name><surname>Lifton</surname><given-names>RP</given-names></name>
<name><surname>Willimas</surname><given-names>CS</given-names></name>
<name><surname>Charru</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Molecular basis of human hypertension; role of angiotensinogen</article-title>. <source>Cell</source> <year>1992</year>; <volume>71</volume>: <fpage>169</fpage>–<lpage>180</lpage>.</citation>
</ref>
<ref id="bibr18-1470320311430990">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stobdan</surname><given-names>T</given-names></name>
<name><surname>Ali</surname><given-names>Z</given-names></name>
<name><surname>Khan</surname><given-names>AP</given-names></name>
<name><surname>Nejatizadeh</surname><given-names>A</given-names></name>
<name><surname>Ram</surname><given-names>R</given-names></name>
<name><surname>Thinlas</surname><given-names>T</given-names></name><etal/>
</person-group>. <article-title>Polymorphism of renin-angiotensin system genes as a risk factor for high-altitude pulmonary edema</article-title>. <source>J Renin Angiotensin Aldosterone Syst</source> <year>2011</year>; <volume>12</volume>: <fpage>93</fpage>–<lpage>101</lpage>.</citation>
</ref>
<ref id="bibr19-1470320311430990">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Henderson</surname><given-names>SO</given-names></name>
<name><surname>Haiman</surname><given-names>CA</given-names></name>
<name><surname>Mack</surname><given-names>W</given-names></name>
</person-group>. <article-title>Multiple polymorphisms in the renin–angiotensin–aldosterone system (ACE, CYP11B2, AGTR1) and their contribution to hypertension in African Americans and Latinos in multiethnic cohort</article-title>. <source>Am J Med Sci</source> <year>2004</year>; <volume>328</volume>: <fpage>266</fpage>–<lpage>273</lpage>.</citation>
</ref>
<ref id="bibr20-1470320311430990">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chung</surname><given-names>WK</given-names></name>
<name><surname>Deng</surname><given-names>L</given-names></name>
<name><surname>Carroll</surname><given-names>S</given-names></name>
<name><surname>Mallory</surname><given-names>N</given-names></name>
<name><surname>Diamond</surname><given-names>B</given-names></name>
<name><surname>Rosenzweig</surname><given-names>EB</given-names></name><etal/>
</person-group>. <article-title>Polymorphism in angiotensin II type 1 receptor (AGTR1) is associated with age at diagnosis in pulmonary arterial hypertension</article-title>. <source>J Heart and Lung Transplantation</source> <year>2009</year>; <volume>28</volume>: <fpage>372</fpage>–<lpage>379</lpage>.</citation>
</ref>
<ref id="bibr21-1470320311430990">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Koehle</surname><given-names>MS</given-names></name>
<name><surname>Wang</surname><given-names>P</given-names></name>
<name><surname>Guenette</surname><given-names>JA</given-names></name>
<name><surname>Rupert</surname><given-names>JL</given-names></name>
</person-group>. <article-title>No association between variants in the ACE and angiotensin II receptor I genes and acute mountain sickness in Nepalese pilgrims to the Janai Purnima Festivals at 4380m</article-title>. <source>High Alt Med Biol</source> <year>2006</year>; <volume>7</volume>: <fpage>281</fpage>–<lpage>289</lpage>.</citation>
</ref>
<ref id="bibr22-1470320311430990">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alvarez</surname><given-names>R</given-names></name>
<name><surname>Terrados</surname><given-names>N</given-names></name>
<name><surname>Ortolano</surname><given-names>R</given-names></name>
<name><surname>Iglesias-Cubero</surname><given-names>G</given-names></name>
<name><surname>Reguero</surname><given-names>JR</given-names></name>
<name><surname>Batalla</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Genetic variation in the renin–angiotensin system and athletic performance</article-title>. <source>Eur J Appl Physiol</source> <year>2000</year>; <volume>82</volume>: <fpage>117</fpage>–<lpage>120</lpage>.</citation>
</ref></ref-list>
</back>
</article>